Goldman Sachs’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Goldman Sachs’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27,628	Closed	-$658K	–	6601
2021 Q4	$658K	Buy	+27,628	New	+$768K	﹤0.01%	5183
2021 Q2	–	Sell	-19,944	Closed	-$597K	–	6229
2021 Q1	$597K	Buy	19,944 +2,334	+13%	+$76K	﹤0.01%	4986
2020 Q4	$559K	Hold	17,610	–	–	﹤0.01%	4544
2020 Q3	$484K	Hold	17,610	–	–	﹤0.01%	4500
2020 Q2	$477K	Hold	17,610	–	–	﹤0.01%	4400
2020 Q1	$344K	Hold	17,610	–	–	﹤0.01%	4422
2019 Q4	$413K	Buy	+17,610	New	+$373K	﹤0.01%	4605

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Goldman Sachs's CNCR Position: Q1 2022 in Review

Goldman Sachs sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2022, closing a stake of 27,628 shares — an estimated $658K sold.

Goldman Sachs first reported a position in CNCR in Q4 2019 and held it in 7 quarters. The position peaked at $658K in Q4 2021. 20 funds tracked by Wall St. Rank hold CNCR as of Q1 2022.

Goldman Sachs reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 27,628 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2022, an estimated $658K.
Goldman Sachs first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2019 and held it in 7 quarters.
Goldman Sachs's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $658K in Q4 2021.
20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.